Where Was Retatrutide Injected in Clinical Trials? Subcutaneous Site Education

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited

Key Takeaways

• Retatrutide is investigational and not FDA-approved. FormBlends does not supply retatrutide. This material describes what trial protocols and standard subcutaneous peptide practice involve, framed educationally
• Phase 2 trials used subcutaneous injection into abdomen, thigh, or upper arm, the same three sites used for semaglutide, tirzepatide, and insulin
• The abdomen is typically the most accessible site for self-administration, with the most consistent subcutaneous fat layer across body types
• Site rotation reduces lipohypertrophy and local irritation. Standard practice is to vary the exact site within the chosen area each week
• Subcutaneous peptide administration is straightforward in principle but requires training; this material is educational, not a step-by-step injection guide

Direct answer

In Phase 2 clinical trials, retatrutide was administered by subcutaneous injection into the abdomen, thigh, or upper arm, consistent with the standard sites for subcutaneous peptide therapy. Patients were trained to rotate sites week to week to reduce skin and tissue irritation. The injection is into the fatty layer just under the skin, not into muscle or vein. Retatrutide is investigational and not FDA-approved; FormBlends does not supply it. Any peptide injection should be discussed with a licensed clinician and performed under their supervision and training.

Table of contents

1. What "subcutaneous" actually means
2. The three standard injection sites
3. Why the abdomen is the default site
4. Thigh injection considerations
5. Upper arm injection considerations
6. Site rotation practice
7. How injection site affects absorption
8. What clinical trial training included
9. Why this is not a how-to guide
10. Decision framework: patient, clinician, researcher
11. FAQ
12. Sources

What "subcutaneous" actually means

Subcutaneous (often abbreviated SC or SQ) refers to the layer of fatty tissue between the skin (dermis) and the underlying muscle. This layer is the target for many injectable medications, particularly peptides and proteins that need slow, gradual absorption.

The subcutaneous space has several physical properties that matter for drug delivery:

• Lower blood flow than muscle, which slows absorption and produces a more gradual plasma drug concentration curve
• Larger volume than intramuscular routes, which can accept doses up to about 1-1.5 mL comfortably
• Less pain at injection compared to intramuscular routes because there are fewer nerve endings in fat tissue
• Lower infection risk than intravenous routes because the depot of drug is not in direct contact with the bloodstream

Peptide drugs are well-suited to subcutaneous delivery because their large molecular size limits oral absorption, and their long half-lives benefit from the slow release that subcutaneous depots provide.

The three standard injection sites

The standard sites for subcutaneous peptide injection, consistent across approved GLP-1 medications and used in Phase 2 retatrutide trials, are:

1. Abdomen. Specifically the lower abdomen, at least 2 inches (5 cm) away from the navel, avoiding scars and stretch marks
2. Thigh. The front and outer thigh, in the middle third (not too close to the hip or knee), avoiding the inner thigh and back of the thigh
3. Upper arm. The upper outer arm, in the area where the deltoid muscle thickens above the bicep. This site usually requires assistance from another person because of the angle

Each of these areas has adequate subcutaneous fat in most adults, is accessible for injection (with the upper arm requiring help), and avoids major nerves and blood vessels at typical injection depths.

FDA labels for approved analogous peptides (Ozempic, Wegovy, Mounjaro, Zepbound) list the same three sites. Clinical trial protocols for retatrutide followed the same convention.

Why the abdomen is the default site

Most patients and most protocols default to the abdomen for several reasons:

• Visibility. The patient can see the injection site clearly without contortion
• Consistency. The lower abdomen has reasonably consistent subcutaneous fat in most adults across body sizes
• Area for rotation. The abdomen offers a large area for site rotation, allowing weekly injections at different spots for many months without revisiting the same exact location
• Absorption rate. Abdominal absorption is typically slightly faster than thigh or arm, which can be a small clinical advantage for medications where consistent plasma levels matter

The standard convention is to use the area around the lower abdomen but at least 2 inches away from the umbilicus (navel). The umbilicus itself and the area immediately surrounding it have less subcutaneous fat and more scar tissue, so injection there is uncomfortable and produces unpredictable absorption.

Scars from previous surgeries (cesarean section, appendectomy, hernia repair) are avoided. Scar tissue has altered blood flow and unpredictable subcutaneous fat distribution, both of which can affect absorption.

Thigh injection considerations

The thigh is a reasonable alternative to the abdomen and is sometimes preferred by patients who find abdominal injection uncomfortable. The specific landing zone is:

• The front (anterior) thigh, in the middle third between hip and knee
• The outer (lateral) thigh, similar middle-third zone
• Not the inner (medial) thigh, which is closer to femoral blood vessels
• Not the back (posterior) of the thigh, which is more difficult to reach and has more variable subcutaneous fat

Subcutaneous fat in the thigh varies more by body composition than the abdomen does. Patients with very lean thighs may not have adequate subcutaneous space for injection; the abdomen is a better default in those cases.

Thigh injection has slightly slower absorption than abdomen, by roughly 25-30% based on insulin pharmacokinetic data. For weekly peptides with long half-lives, this difference is clinically minor.

Upper arm injection considerations

The upper outer arm is the third standard site. Specific anatomy:

• The fleshy area on the upper outer arm, between the shoulder and the bicep insertion
• Not the inner arm, which has thinner subcutaneous fat and more visible blood vessels
• Not the area over the deltoid muscle directly, which is the intramuscular injection site for vaccines

Self-administration in the upper arm is difficult because the patient must reach across their body or twist awkwardly to inject. Most self-administering patients use abdomen or thigh; upper arm is more common when a caregiver, partner, or clinician administers the injection.

Absorption from the upper arm is intermediate between abdomen (fastest) and thigh (slowest) in insulin pharmacokinetic studies. For long-acting peptides, the difference is small.

Site rotation practice

Repeated injection at the exact same spot can produce two problems:

Lipohypertrophy. The fatty tissue at the repeated injection site can thicken into firm, sometimes visible lumps. Insulin-using diabetic patients have long-established literature on this; the same mechanism applies to other subcutaneous peptide therapies. Lipohypertrophic tissue absorbs drug erratically, which produces inconsistent dosing.

Local irritation. Repeated trauma to the same spot can cause persistent redness, tenderness, or skin changes. Site rotation lets each spot heal between exposures.

Standard rotation practice for weekly injections:

• Pick a primary site (abdomen, thigh, or arm)
• Each week, inject at a different spot within that area, separated by at least 1 inch from the previous week's spot
• Return to the same exact spot only after several weeks, ideally a month or more
• Mentally map the area as a grid; some patients use a small notebook or app to track

Across the chosen area, the goal is to spread injections so no single spot bears repeated trauma over short windows.

How injection site affects absorption

Absorption from subcutaneous depots depends on local blood flow. The abdomen has the highest baseline blood flow, the thigh the lowest, with the arm in between. For insulin (extensively studied), absorption rates differ by 20-30% between sites under standard conditions.

Several factors modify local blood flow at any site:

• Exercise of the muscle near the injection site increases local circulation and can accelerate absorption
• Heat (hot shower, sauna, heating pad) increases blood flow and absorption
• Cold (ice pack, cold weather) decreases blood flow and slows absorption
• Massage of the injection site can change absorption, generally accelerating it

For long-acting peptides (semaglutide, tirzepatide, retatrutide) with half-lives of multiple days, modest absorption rate differences average out across the dosing interval. The dose-to-blood-level curve is dominated by the long half-life, not the initial absorption rate.

This is different from short-acting medications like rapid insulin, where site choice can produce clinically meaningful differences in onset of action. For weekly GLP-1 family peptides, site choice is largely a comfort and convenience decision.

What clinical trial training included

The Phase 2 retatrutide trial (Jastreboff et al., New England Journal of Medicine 2023) enrolled 338 patients across multiple sites. Trial protocols typically include detailed patient training before the first self-administered injection. Training elements common across trials of injectable peptides:

• Hand hygiene and skin preparation (alcohol swab, allow to dry)
• Vial inspection (clear solution, no particulates, within stability window)
• Dose drawing into the syringe with air-bubble removal
• Injection technique (typically 90-degree angle for adults with adequate subcutaneous fat, 45-degree angle for thinner patients)
• Site rotation between injections
• Disposal of used syringe in a sharps container
• Recognition of adverse events and when to call the study team

Trials require demonstration of competence before sending patients home with study product. Patients who cannot self-administer reliably use a caregiver or partner. Some trials require the first one or several injections to be administered at the trial site under supervision.

Why this is not a how-to guide

This article describes injection sites and absorption principles for educational purposes. It is not a step-by-step instruction for performing injections. Several reasons:

First, retatrutide is investigational. It is not legally dispensed for outpatient use in the U.S. as of May 2026. Clinical trial enrollment is the legitimate pathway, and trial participants receive in-person training rather than reading articles.

Second, injection technique requires hands-on training that text cannot fully convey. The angle of the needle, the depth, the speed of injection, the management of bubble formation, the response to bleeding or pain at the site, all of these involve judgments that develop with practice under supervision.

Third, patient-specific factors (body composition, comorbidities, medication interactions, prior surgical history) affect injection decisions. These are not generic.

Fourth, adverse events do occur. Recognizing them and knowing when to seek medical attention is part of the training that comes with clinician oversight.

For patients on FDA-approved subcutaneous peptide medications (semaglutide, tirzepatide, insulin), the prescribing clinician and dispensing pharmacy provide injection training. Manufacturer-provided patient instruction sheets and videos supplement this training. Both are appropriate to follow.

Decision framework: patient, clinician, researcher

If you are a patient researching retatrutide:

• The product is not legally available for outpatient prescription in the U.S.
• Clinical trial enrollment is the only legitimate pathway under medical supervision
• FDA-approved alternatives (semaglutide, tirzepatide) follow the same subcutaneous injection sites and similar protocols
• Injection training comes from the prescriber, not from articles

If you are a clinician:

• Patient questions about retatrutide self-administration sometimes signal access through non-pharmacy channels
• The conversation about identity verification, sterile technique, and supervised injection training is appropriate to document
• FDA-approved alternatives with extensive safety data should be the first-line consideration

If you are a clinical trial participant:

• Follow the training and instructions provided by your trial site
• Report adverse events or injection-site reactions to the study team promptly
• The trial protocol is the source of truth for site choice, rotation schedule, and technique

FAQ

Where was retatrutide injected in clinical trials? Subcutaneously in the abdomen, thigh, or upper arm, consistent with standard subcutaneous peptide practice. Patients rotated sites weekly. Retatrutide is investigational; FormBlends does not supply it.

What does subcutaneous injection mean? Injection into the fatty tissue just under the skin, between the dermis and the underlying muscle. The standard route for many peptide therapeutics.

Why is the abdomen a common injection site? Most accessible subcutaneous fat layer, large area for site rotation, easy to see during self-administration, consistent absorption.

Can retatrutide be injected in the thigh? Yes. The front and outer thigh are standard sites. Avoid the inner thigh (proximity to blood vessels) and posterior thigh (variable subcutaneous fat).

What about upper arm injections? The upper outer arm is acceptable. Self-administration is difficult; assistance is often needed.

How often should injection sites be rotated? Standard practice for weekly injections is to use a different spot within the chosen area each week, returning to the same exact spot only after several weeks.

Does injection site affect retatrutide absorption? Modest differences exist (abdomen fastest, thigh slowest, arm intermediate). For long-acting weekly peptides, the differences are clinically minor because the long half-life dominates the plasma level curve.

Why does this require medical supervision? Dose calculation, sterile technique, site choice, side effect monitoring, and dose titration all benefit from clinician oversight. Retatrutide specifically is investigational and not legally dispensed for outpatient use.

What needle gauge is used for subcutaneous peptide injection? Typically 29-31 gauge insulin syringes (very thin needles) with 4-8 mm length. Shorter needles are appropriate for thinner subcutaneous fat layers.

What if I see bleeding at the injection site? Minor bleeding is common and typically stops with gentle pressure. Significant bleeding, persistent oozing, or bruising should be discussed with the prescriber. Avoid injecting near visible surface veins.

Related guides

• Retatrutide Side Effects: What Clinical Trials Reveal
• Retatrutide Clinical Trials 2026: Every TRIUMPH Study Explained
• Retatrutide Liver Fat Reduction: 86% Decrease in Clinical Trials
• Retatrutide Expanded Access Clinical Trials
• Retatrutide and Injection Site Reactions: What to Expect and How to Manage
• Retatrutide Trial Demographics: Who Was Studied?

Sources

1. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526.
2. FDA Prescribing Information: Ozempic (semaglutide injection). Novo Nordisk. Updated 2024.
3. FDA Prescribing Information: Wegovy (semaglutide injection). Novo Nordisk. Updated 2024.
4. FDA Prescribing Information: Mounjaro (tirzepatide injection). Eli Lilly. Updated 2024.
5. FDA Prescribing Information: Zepbound (tirzepatide injection). Eli Lilly. Updated 2024.
6. American Diabetes Association. Standards of Medical Care in Diabetes: Insulin Administration. Updated 2024.
7. Frid AH, Hirsch LJ, Menchior AR, et al. Worldwide Injection Technique Questionnaire Study: Population Parameters and Injection Practices. Mayo Clinic Proceedings. 2016;91(9):1212-1223.
8. Blanco M, Hernandez MT, Strauss KW, Amaya M. Prevalence and Risk Factors of Lipohypertrophy in Insulin-Injecting Patients with Diabetes. Diabetes & Metabolism. 2013;39(5):445-453.
9. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
10. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
11. U.S. Food and Drug Administration. Guidance for Industry: Patient Counseling Information for Self-Administered Injectable Products. 2014.
12. Eli Lilly and Company. Pipeline Disclosure: Retatrutide Phase 3 Trials. SEC filings 2024-2025.

Footer disclaimers

Platform Disclaimer. FormBlends operates a digital health platform that connects patients to U.S.-licensed providers and state-licensed pharmacies. We do not manufacture, prescribe, or dispense medication. We do not sell or supply retatrutide. All clinical decisions belong to the patient and an independent licensed prescriber.

Compounded Medication Notice. Compounded medications from state-licensed 503A pharmacies follow USP 797 standards but are not FDA-approved. They are not interchangeable with FDA-approved products.

Results Disclaimer. Injection site information here describes clinical trial practice and standard subcutaneous peptide administration. It is educational, not a step-by-step injection instruction. Patient-specific injection training should come from a licensed clinician.

Trademark Notice. Retatrutide is the developmental designation for an investigational compound from Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with the named companies.